The University of Chicago Header Logo

Connection

Sandeep Gurbuxani to Mutation

Back to Details
This is a "connection" page, showing publications Sandeep Gurbuxani has written about Mutation.
Sandeep Gurbuxani
Connection Strength
0.765
Mutation
  1. Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 06 18; 14(1):99.
    View in: PubMed
    Score: 0.105
  2. Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 May 01; 5(3):164-179.
    View in: PubMed
    Score: 0.104
  3. SETBP1 sets the stage. Blood. 2024 04 04; 143(14):1323-1324.
    View in: PubMed
    Score: 0.103
  4. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood. 2004 Jan 15; 103(2):399-406.
    View in: PubMed
    Score: 0.100
  5. On a WHIM. Blood. 2013 Feb 07; 121(6):875.
    View in: PubMed
    Score: 0.048
  6. Malignant progression of preleukemic disorders. Blood. 2024 05 30; 143(22):2245-2255.
    View in: PubMed
    Score: 0.026
  7. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024 Apr; 204(4):1238-1242.
    View in: PubMed
    Score: 0.025
  8. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome. Blood Cells Mol Dis. 2003 Nov-Dec; 31(3):351-6.
    View in: PubMed
    Score: 0.025
  9. Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.
    View in: PubMed
    Score: 0.025
  10. Oncogenic RAS promotes leukemic transformation of CUX1-deficient cells. Oncogene. 2023 03; 42(12):881-893.
    View in: PubMed
    Score: 0.024
  11. Type I but Not Type II Calreticulin Mutations Activate the IRE1a/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms. Blood Cancer Discov. 2022 07 06; 3(4):298-315.
    View in: PubMed
    Score: 0.023
  12. Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype. Br J Haematol. 2022 06; 197(6):736-744.
    View in: PubMed
    Score: 0.022
  13. LKB1/STK11 Is a Tumor Suppressor in the Progression of Myeloproliferative Neoplasms. Cancer Discov. 2021 06; 11(6):1398-1410.
    View in: PubMed
    Score: 0.021
  14. Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations. Blood Adv. 2020 10 13; 4(19):4873-4886.
    View in: PubMed
    Score: 0.020
  15. Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51.
    View in: PubMed
    Score: 0.020
  16. Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles. Cancer Res. 2016 08 01; 76(15):4470-80.
    View in: PubMed
    Score: 0.015
  17. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat Med. 2015 Dec; 21(12):1473-80.
    View in: PubMed
    Score: 0.014
  18. AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia. 2013 Sep; 27(9):1882-90.
    View in: PubMed
    Score: 0.012
  19. Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell. 2012 Oct 16; 22(4):524-35.
    View in: PubMed
    Score: 0.012
  20. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. J Clin Invest. 2012 Mar; 122(3):948-62.
    View in: PubMed
    Score: 0.011
  21. FOG-1-mediated recruitment of NuRD is required for cell lineage re-enforcement during haematopoiesis. EMBO J. 2010 Jan 20; 29(2):457-68.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.